{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:26:48Z","timestamp":1787171208318,"version":"build-2736575974"},"reference-count":62,"publisher":"American Society of Clinical Oncology (ASCO)","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Oncol Pract"],"abstract":"<jats:p>Exagamglogene autotemcel, the first clustered regularly interspaced short palindromic repeats (CRISPR)\u2013based gene-editing therapy to enter clinical practice, has established genome editing as a curative-intent option for eligible patients with severe sickle cell disease (SCD) and transfusion-dependent \u03b2-thalassemia (TDT). Ex vivo CRISPR-Cas9 editing of autologous CD34-positive hematopoietic stem and progenitor cells to reactivate fetal hemoglobin has produced durable freedom from severe vaso-occlusive crises in SCD and sustained transfusion independence in TDT. This approach offers a donor-independent alternative to allogeneic hematopoietic stem-cell transplantation without graft rejection or graft-versus-host disease. Hemoglobinopathies, therefore, provide the first clinically validated delivery model for CRISPR therapeutics. Successful implementation, however, requires more than editing efficacy. It depends on structured referral, candidacy assessment, organ function review, mobilization and collection, centralized manufacturing, pharmacokinetic-guided myeloablative conditioning, transplant-level supportive care, fertility preservation, psychosocial support, and prolonged surveillance coordinated among primary hematologists and cellular therapy programs. Key barriers include stem cell collection, conditioning-related toxicity, cost, reimbursement friction, and persistent inequities in access. Long-term follow-up and registry participation are necessary to evaluate outcomes beyond pain crises, identify late toxic effects, and compare real-world effectiveness across gene editing, gene addition, and allogeneic transplantation. In oncology, CRISPR-based therapy remains investigational, with early clinical feasibility demonstrated in relapsed or refractory B-cell malignancies, T-cell malignancies, AML, multiple myeloma, and selected solid tumors. For hematologists, oncologists, and transplant and cellular therapy programs, the central challenge is to integrate CRISPR into practice with the rigor required for any high-risk curative therapy: careful patient selection, disciplined delivery, and long-term accountability.<\/jats:p>","DOI":"10.1200\/op-26-00479","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:08Z","timestamp":1787169548000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":0,"title":["Translating CRISPR to Practice in the Clinic: Transformative Therapy in Hemoglobinopathies and Emerging Applications in Malignancies"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7312-4694","authenticated-orcid":true,"given":"Miza","family":"Salim Hammoud","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7518-309X","authenticated-orcid":true,"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic Children's Institute, Cleveland, OH"},{"name":"Taussig Cancer Institute, Cleveland Clinic Cancer Center, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01309-7"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00372-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309676"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309673"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009202"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2023.2235928"},{"key":"e_1_3_4_8_2","first-page":"352.e1","article-title":"Best practices in gene therapy for sickle cell disease and transfusion-dependent \u03b2-thalassemia","volume":"31","author":"Frangoul H","year":"2025","unstructured":"Frangoul H, Stults A, Bruce K, et al: Best practices in gene therapy for sickle cell disease and transfusion-dependent \u03b2-thalassemia. Transpl Cell Ther 31:352.e1-352.e10, 2025","journal-title":"Transpl Cell Ther"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.03.019"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02444-y"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01745-8"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7365"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature20134"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf2444"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature17946"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature24644"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1711-4"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2415550"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215643"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501277"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504835"},{"key":"e_1_3_4_22_2","unstructured":"ClinicalTrials.gov: Transplantation of clustered regularly interspaced short palindromic repeats modified hematopoietic progenitor stem cells (CRISPR_SCD001) in patients with severe sickle cell disease. https:\/\/clinicaltrials.gov\/study\/NCT04774536."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02636-6"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2503294"},{"key":"e_1_3_4_25_2","volume-title":"Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry","author":"U.S. Food and Drug Administration, Center for Biologics Evaluation and Research","year":"2020","unstructured":"U.S. Food and Drug Administration, Center for Biologics Evaluation and Research: Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry. U.S. Department of Health and Human Services, 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/guidance-compliance-regulatory-information-biologics\/biologics-guidances"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S508896"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2025.10806"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2021.09.003"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015413"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.29443"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02782"},{"key":"e_1_3_4_32_2","first-page":"934.e1","article-title":"Safety and feasibility of fertility preservation and fertility outcomes in patients with sickle cell disease and transfusion-dependent \u03b2 thalassemia undergoing gene therapy","volume":"31","author":"Hmaidan S","year":"2025","unstructured":"Hmaidan S, Van Heertum K, Bhatia S, et al: Safety and feasibility of fertility preservation and fertility outcomes in patients with sickle cell disease and transfusion-dependent \u03b2 thalassemia undergoing gene therapy. Transpl Cell Ther 31:934.e1-934.e8, 2025","journal-title":"Transpl Cell Ther"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.01.002"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00175-3"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0118"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2412955"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2513320"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.12.001"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016054"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/trf.18461"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-5956"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6096"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.12.921"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024519"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016701"},{"key":"e_1_3_4_46_2","volume-title":"Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia","author":"Taher AT","year":"2025","unstructured":"Taher AT, Farmakis D, Porter JB, et al: Guidelines for the Management of Transfusion-Dependent \u03b2-Thalassaemia. 5th ed. Nicosia, Cyprus: Thalassaemia International Federation, 2025","edition":"5"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016702"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-6089"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015532"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7025"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7031"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025028387"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2505478"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS6586"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.02.037"},{"key":"e_1_3_4_57_2","article-title":"Remission of tumor protein p53 gene (TP53)-mutant AML after transplantation with trem-cel, a CRISPR\/Cas9 gene-edited allograft lacking CD33, followed by a donor-derived anti-CD33 chimeric antigen receptor T cell therapy","author":"Koehne G","unstructured":"Koehne G, Mushtaq MU, Muffly LS, et al: Remission of tumor protein p53 gene (TP53)-mutant AML after transplantation with trem-cel, a CRISPR\/Cas9 gene-edited allograft lacking CD33, followed by a donor-derived anti-CD33 chimeric antigen receptor T cell therapy. JCO Precis Oncol 10.1200\/PO-25-00556","journal-title":"JCO Precis Oncol"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025031053"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0102"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00749-x"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102010"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00083-X"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-68112-6"}],"container-title":["JCO Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OP-26-00479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:59:10Z","timestamp":1787169550000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OP-26-00479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":62,"alternative-id":["10.1200\/OP-26-00479"],"URL":"https:\/\/doi.org\/10.1200\/op-26-00479","relation":{},"ISSN":["2688-1527","2688-1535"],"issn-type":[{"value":"2688-1527","type":"print"},{"value":"2688-1535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"2026-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-08","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"OP-26-00479"}}